52 results about "Streptococcus pneumoniae pneumonia" patented technology

The present invention relates to the total synthesis of saccharide structures contained in the capsular polysaccharide of Streptococcus pneumoniae type 1, to glycoconjugates containing said saccharide structures obtained by total synthesis and to use of such glycoconjugates and pharmaceutical compositions thereof in the immunization against diseases associated with bacteria containing said saccharide structures in their capsular polysaccharide, and more specifically associated with Streptococcus pneumoniae.

The invention provides the application of Streptococcus pneumoniae protein in resisting Streptococcus pneumoniae infection. The Streptococcus pneumoniae endopeptidase O (PepO) of the present invention is a subcutaneous immune adjuvant, mixed and fused with the 673rd to 863rd amino acid peptide of zinc metalloprotease B (ZmpB), and the prepared Streptococcus pneumoniae Protein vaccines have a good protective effect against Streptococcus pneumoniae infection.

The invention provides a gene segment of chemosynthetic streptococcus pneumoniae surface adhesin A as well as expression and application of the gene segment, and relates to the fields of a genetic engineering technology and diagnostic reagents. A bran-new gene sequence of an epitope is chemically synthesized by screening out a strong antigen epitope and total 197 amino acids from the 84th amino acid to the 280th amino acid in streptococcus pneumoniae adhesin A through computer analysis and selecting a codon which a procaryotic organism prefers. The genetic engineering technology is used for expressing the gene segment and preparing a strong antigen epitope segment of the streptococcus pneumoniae adhesin A. Expressed protein can be used for vaccine research and development, detection of streptococcus pneumoniae infection antibodies and preparation of monoclonal antibodies and polyclonal antibodies.

The invention relates to antibodies for resisting human streptococcus pneumoniae fam2 family PspA protein and an immunochromatographic kit applying the antibodies to detection on human streptococcus pneumoniae. The antibodies for resisting the human streptococcus pneumoniae fam2 family PspA protein are used for recognizing two linear antigenic epitopes composed of 34-47 amino acids and 274-287 amino acids of the human streptococcus pneumoniae fam2 family PspA protein respectively, and the sequence number of the human streptococcus pneumoniae fam2 family PspA protein in GenBank is WP_054380072.1; the sequences of the 34-47 amino acids and the 274-287 amino acids of the human streptococcus pneumoniae fam2 family PspA protein are SPQVVEKSSLEKKY and KLLDSLDPEGKTQD respectively. The two rabbit antibodies for resisting the human streptococcus pneumoniae fam2 family PspA protein have the advantages of being good in specificity, high in purity and titer and low in preparation cost.

The present invention provides a macrocyclic lactone and quinolone hybrid, characterized in that the macrocyclic lactone and quinolone hybrid include compounds with general formula I and general formula II, or, the macrocyclic lactone and quinolone hybrids include pharmaceutically acceptable salts formed by compounds of the general formula I and II and inorganic acids or organic acids, and the macrolide and quinolone hybrids can be better adapted to industrial production , and has good anti-susceptible and anti-drug resistance against common clinical erythromycin-resistant Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Mora catarrhalis and Haemophilus influenzae Bacterial activity, can effectively treat clinical bacterial pneumonia or pneumonia caused by other microorganisms (such as mycoplasma, Legionella, etc.), and other tissue infections;

The invention discloses the application of SPD_0310 protein as a target in the preparation of medicines for preventing and treating Streptococcus pneumoniae infection. In the present invention, it was found that the expression level of SPD_0310 in the triple mutant strain in which the three main iron transport genes of Streptococcus pneumoniae were knocked out at the same time was increased and could grow normally, indicating that the SPD_0310 protein may be involved in the interaction of various iron transport proteins. The present invention also found that the spd_0310 gene knockout strain has reduced infectivity to mice. Based on this, SPD_0310 can be used to prepare antibodies to the protein, so as to facilitate the development of antibody drugs. In addition, the present invention also found that the active center of the protein can bind heme, and proved that porphyrins can be used as substrates to compete with heme, indicating that porphyrins can be used as inhibitors of SPD_0310 to inhibit Streptococcus pneumoniae toxicity, which has broad application prospects in the field of antibacterial drugs.